Abstract: An adjuvant composition comprising monophosphoryl lipid A or a derivative of monophposphoryl lipid A adsorbed onto an aluminium salt particle.
Abstract: The present invention relates to a method for the production of a hepatitis B antigen suitable for use in a vaccine, the method comprising purification of the antigen in the presence of cysteine, to vaccines comprising such antigens.
Type:
Grant
Filed:
December 23, 2008
Date of Patent:
January 7, 2014
Assignee:
Glaxosmithkline Biologicals, S.A.
Inventors:
Koen De-Heyder, Peter Schu, Michelle Serantoni, Omer Van-Opstal
Abstract: The invention relates to infectious clones of parvovirus B19, methods of cloning infectious B19 clones, and methods of cloning viral genomes that have secondary DNA structures that are unstable in bacterial cells. A B19 infectious clone and methods of producing B19 infectious clones are useful for producing infectious virus. Infectious virus is useful for identifying and developing therapeutically effective compositions for treatment and/or prevention of human parvovirus B19 infections.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
December 10, 2013
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Institut National de Rechesche Scientifique
Inventors:
Kevin Edward Brown, Ning Zhi, Peter Tijssen, Zoltan Zadori
Abstract: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.
Type:
Grant
Filed:
February 5, 2010
Date of Patent:
November 26, 2013
Assignees:
Mount Sinai School of Medicine, Memorial Sloan-Kettering Cancer Center
Inventors:
Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Yuman Fong
Abstract: A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided.
Type:
Grant
Filed:
May 31, 2007
Date of Patent:
November 26, 2013
Assignees:
Toray Industries, Inc., Osaka University
Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
Type:
Grant
Filed:
June 1, 2010
Date of Patent:
November 26, 2013
Assignee:
ABL SA
Inventors:
Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.
Type:
Grant
Filed:
December 22, 2008
Date of Patent:
November 26, 2013
Assignee:
Universitat Zurich
Inventors:
Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
Abstract: Disclosed herein are chimeric TBEV/DEN4 flaviviruses including a first nucleic acid molecule including a 5? non-coding region (NCR) from a DEN4 virus, a nucleic acid encoding a C protein and non-structural proteins from a DEN4 virus, and a 3? NCR from a DEN4 virus, wherein nonstructural protein NS4B includes a phenylalanine at amino acid position 112, nonstructural protein NS5 includes an alanine at amino acid position 654 and an alanine at amino acid position 655, and the 3? NCR includes a deletion of nucleotides 10478-10507. The chimeric construct also includes a second nucleic acid molecule, which is operably linked to the first nucleic acid molecule, encoding a prM protein and an E protein from a TBEV, wherein the E protein includes an amino acid substitution that differs from the wild type TBEV at amino acid position 315 and a tryptophan at amino acid position 240.
Type:
Grant
Filed:
May 28, 2010
Date of Patent:
October 29, 2013
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Alexander G. Pletnev, Brian R. Murphy, Amber R. Engel
Abstract: Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed.
Abstract: The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.
Type:
Grant
Filed:
September 23, 2011
Date of Patent:
September 24, 2013
Assignee:
Transgene S.A.
Inventors:
Anne Fournillier, Genevieve Inchauspe, Jean-Daniel Abraham, Maria Dimitrova-Tchomakov, Marie Parnot
Abstract: The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.
Type:
Grant
Filed:
August 24, 2007
Date of Patent:
September 17, 2013
Assignee:
The MacFarlane Burnet Institute for Medical Research and Public Health Limited
Abstract: A composition comprising an isolated fowl adenovirus (FAdV), wherein the FAdV is a strain selected from FAdV-2, FAdV-7, FAdv-8a, FAdV-8b, FAdV-8a/8b or FAdV-11 serotype strains; and a suitable carrier and methods for inducing protective immunity in a subject and/or its progeny.
Type:
Grant
Filed:
December 15, 2010
Date of Patent:
September 3, 2013
Assignees:
University of Saskatchewan, University of Guelph
Abstract: A method for detecting at least one antibody directed against at least one primate immunodeficiency virus in a biological sample that includes contacting a biological sample with (i) at least one detection multiple antigenic peptide comprising a portion of an immunodominant region of a transmembrane protein of a primate immunodeficiency virus and (ii) at least one differentiation multiple antigenic peptide comprising a portion of a V3-loop of an envelope protein of a primate immunodeficiency virus. Also disclosed is an enzyme immunoassay that includes a first substrate to which are bound at least one of the detection multiple antigenic peptides and a second substrate to which are bound at least one of the differentiation multiple antigenic peptides.
Type:
Grant
Filed:
March 4, 2010
Date of Patent:
September 3, 2013
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Marcia L. Kalish, Clement B. Ndongmo, Chou-Pong Pau, William M. Switzer, Thomas M. Folks
Abstract: Disclosed herein is the finding that baculovirus display of multiple influenza virus hemagglutinin (HA) proteins elicits broadly reactive immune responses against influenza. Thus provided herein are recombinant baculovirus vectors having a first, second, third and fourth nucleic acid sequence, each encoding an influenza hemagglutinin (HA) fusion protein. The first, second, third and fourth nucleic acid sequences each encode an influenza HA with a different amino acid sequence. Also provided are recombinant baculoviruses displaying a first, second, third and fourth influenza virus HA fusion protein in the baculovirus envelope, wherein each HA fusion protein comprises a different HA amino acid sequence. Tetravalent influenza virus vaccines comprising the recombinant baculoviruses disclosed herein are further provided. In addition, methods of immunizing a subject against influenza virus using the tetravalent influenza virus vaccines are provided.
Type:
Grant
Filed:
September 12, 2011
Date of Patent:
August 20, 2013
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.
Abstract: The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention.
Type:
Grant
Filed:
April 6, 2011
Date of Patent:
July 23, 2013
Assignee:
Oncolytics Biotech Inc.
Inventors:
Donald Morris, Bradley G. Thompson, Matthew C. Coffey
Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.
Type:
Grant
Filed:
August 22, 2007
Date of Patent:
July 9, 2013
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Qui-Lim Choo, Jang Han, Michael Houghton, Taewoo Kwon, Hyun Chul Song, Yifei Zhu